These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 30811293)

  • 1. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
    Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
    J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
    Flinn IW; van der Jagt R; Kahl BS; Wood P; Hawkins TE; Macdonald D; Hertzberg M; Kwan YL; Simpson D; Craig M; Kolibaba K; Issa S; Clementi R; Hallman DM; Munteanu M; Chen L; Burke JM
    Blood; 2014 May; 123(19):2944-52. PubMed ID: 24591201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
    Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
    Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
    Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
    Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario.
    Suleman A; Aktar SJ; Ante Z; Liu N; Chan KKW; Cheung MC; Prica A
    Br J Haematol; 2023 Sep; 202(6):1104-1118. PubMed ID: 37474340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
    Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
    J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study.
    Li W; Chang Y; Liu X; Chen Z; Sun J; Geng Z; Zhang M; Zhang L
    Ann Hematol; 2024 Jun; 103(6):2003-2012. PubMed ID: 38308020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
    Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
    J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
    Edina BC; Rinaldi I
    Acta Med Indones; 2022 Apr; 54(2):316-323. PubMed ID: 35818660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
    Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
    Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
    Vidal L; Gafter-Gvili A; Gurion R; Raanani P; Dreyling M; Shpilberg O
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009045. PubMed ID: 22972131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
    Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
    Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.
    Villa D; Sehn LH; Savage KJ; Toze CL; Song K; den Brok WD; Freeman CL; Scott DW; Gerrie AS
    Blood Adv; 2020 Aug; 4(15):3486-3494. PubMed ID: 32735654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
    Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Geisler CH; Trneny M; Stilgenbauer S; Kaiser F; Doorduijn JK; Salles G; Szymczyk M; Tilly H; Kanz L; Schmidt C; Feugier P; Thieblemont C; Zijlstra JM; Ribrag V; Klapper W; Pott C; Unterhalt M; Dreyling MH
    J Clin Oncol; 2020 Jan; 38(3):248-256. PubMed ID: 31804876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
    Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
    Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.